Centaur Pharmaceuticals Pvt Ltd. on Thursday announced the launch of a generic version of chronic heart failure drug Corlanor in the United States.
According to company’s statement, Centaur received 180-day exclusivity on generic Ivabradine hydrochloride. The Mumbai-based company, through its marketing partner Ingenus Pharmaceuticals, launched Ivabradine in a dosage of 5mg and 7.5mg tablets in the US.
The US Food and Drug Administration lists ivabradine hydrochloride as a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated:
- To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
- For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages six months and older.
“Ivabradine launch presents an opportunity for Centaur to expand share in the chronic heart failure drug market in the US,” said S.D Sawant, Chairman and Managing Director, Centaur Pharmaceuticals. “The company will maintain international focus and keep exploring strategic alliances and in-licensing of molecules to boost its growth.”
Centaur Pharmaceuticals ranks among India’s few, fully integrated pharmaceutical firms with proficiencies across the pharmaceutical value chain, it claimed. Centaur leverages its synergies across active pharma ingredients, R&D, contract research and manufacturing, clinical research and formulations, it stated.
Centaur generates 42% of its revenue from the international market though exports to 96 countries, the company said in a statement.
“Centaur successfully co-developed a globally patented new chemical entity, DPOCL (Trade name: WOXHEAL), for treating diabetic foot ulcer, an unmet medical need. Centaur’s clinical research division, Lifesan, collaborated with a German biotechnology company and successfully conducted Phase II and III studies in India,” it stated.
